Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes

Review Decision - August 2010 information

Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 73 KB)

Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 73 KB)

Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review): review proposal - April 2010 information

Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review): provisional matrix of stakeholders (PDF 30 KB)

Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review): proposal paper presented to the Institute's Guidance Executive (PDF 194 KB)

Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review): proposal paper presented to the Institute's Guidance Executive (PDF 194 KB)

Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review): provisional matrix of stakeholders (PDF 30 KB)

Review Decision - October 2007 information

Assessment Report: Glycoprotein IIb/IIIa inhibitor guidance for acute coronary syndromes (PDF 990 KB)

Glycoprotein IIb/IIIa Modelling Report (PDF 323 KB)

Review proposal - July 2005 information

Review decision - September 2005 (PDF 79 KB)

Appendix A - Matrix of consultees and commentators. (PDF 41 KB)

Review Proposal August 2007 information

Acute coronary syndromes (PDF 20 KB)

Final Appraisal Determination: The use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes information

Appraisal Consultation Document: Glycoprotein IIb/IIIa Inhibitors information

Assessment report: Glycoprotein IIb/IIIa Antagonists information

Cost-effectiveness model: Glycoprotein Antagonists  information

Cost-effectiveness model: Glycoprotein Antagonists (PDF 957 KB)

A Systematic Review Update of the Clinical Effectiveness and Cost Effectiveness of Glycoprotein IIb/IIIa Antagonists (PDF 3.52 MB)